$SPCX

SpaceX Stock Stalls Around IPO Price: What's Going On? - SpaceX (NASDAQ:SPCX)

SpaceX (NASDAQ:SPCX) shares traded near $132.90, down 0.17% on Monday, after a lockup expiration of 911.5 million insider-held shares that did not trigger expected selling. Morgan Stanley’s Adam Jonas kept an Overweight rating and set a mid-2027 $300 target. Vanda Research said retail turned net sellers by $4.5 million. SpaceX Q2 revenue was $7.81B, up 92% YoY, with a 9-cent per-share loss and $100B cash.

Original reporting
Published Aug 10, 2026, 6:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 7:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SpaceX Stock Stalls Around IPO Price: What's Going On? - SpaceX (NASDAQ:SPCX) — source image
Decision brief

The 30-second read

$SPCXNeutralMed
01

Why it matters

The unlock event appears to have been absorbed without the anticipated sell-off, while Q2 fundamentals (revenue growth, AI segment expansion, large cash and backlog) support the longer-term narrative. The rescheduled Falcon 9 launch is the immediate operational catalyst to monitor.

02

Market read

Traders are likely to weigh whether the unlock overhang is truly cleared against ongoing weakness versus IPO and the next launch outcome.

03

What to watch

The article notes the launch was scrubbed and rescheduled, but does not quantify the reason; technical or regulatory launch issues could reintroduce risk quickly.

Relevance 7/10Novelty 5/10Timing: this week, ahead of the rescheduled Falcon 9 launch on Tuesday morning

Background

SpaceX began trading June 12 and has been trading below its IPO price since mid-July, with a major insider-held share unlock occurring last Thursday.

Company-level read

Ticker impact

$SPCXNeutralMedium confidence
Context

SpaceX shares are trading below IPO price while a lockup expiration passed without the expected sell-off, and the article cites Q2 results and a Falcon 9 launch scrub.

Expected impact

Choppy-to-positive bias if the rescheduled launch proceeds and the unlock selling fails to reappear; downside risk if launch delays recur or insider selling emerges after the unlock window.

Evidence & confidence

The text provides concrete catalysts (unlock dynamics, Q2 revenue and cash/backlog, and a scrubbed then rescheduled Falcon 9 launch) but does not provide new guidance or a definitive post-unlock flow beyond the first day.

Market effects

Could influence sentiment toward space/launch and satellite connectivity names by reinforcing that Starlink demand and cash position remain intact post-unlock.

Limited, primarily US-listed growth/IPO sentiment and retail flow dynamics.

Moderate, as Starlink subscriber growth and launch cadence are globally relevant to satellite communications expectations.

Counterpoint

The absence of immediate unlock selling may be temporary; selling could be deferred into later sessions, keeping pressure on the stock below IPO price.

Key entities

  • SpaceX

    Subject of the article, with insider unlock dynamics, Q2 financial results, and a rescheduled Falcon 9 launch affecting near-term trading.

  • Adam Jonas

    Morgan Stanley analyst cited as describing the unlock as an entry point and reiterating an Overweight view with a mid-2027 price target.

  • Vanda Research

    Cited for retail flow data showing the first net selling day since trading began.

Related articles

$SPCXMed

Why SpaceX Stock Plunged Despite a Strong Q2 Earnings Beat

SpaceX shares fell after its Aug. 4 Q2 results, with a 13.61% drop on Aug. 5. The focus was $18.4B quarterly capex, mostly for AI infrastructure, plus concerns around insider lockup expiration. Q2 revenue rose 92% to $7.81B and net loss narrowed to $541M. Analysts cited AI investment returns; Argus raised to Buy with $160 target and JPMorgan to Overweight with $240.

$TSLAMedAI 8/10

Tesla and SpaceX Committed $16.8 Billion to One Chip Plant. Tesla's Entire Annual Profit Is $3.8 Billion.

Tesla and SpaceX said Aug. 6 they will jointly spend $16.8 billion on the first phase of Terafab, a semiconductor plant in Grimes County, Texas. Tesla cited $3.8 billion net income over the past 12 months and about $43.5 billion cash and investments. The project is described as multiphase, potentially up to $119 billion, with chips for Tesla robots/Cybercab and SpaceX data centers.

$SPCXMed

SpaceX reclaims $135 IPO price in premarket trade Monday

SpaceX’s stock (SPCX) rose about 2.3% in Monday premarket to around $136.20, reclaiming its $135 IPO price. The article cites an Argus upgrade to Buy with a $160 target, limited insider selling after Aug. 6 unlocks, and SpaceX and Tesla’s planned $16.8B “Terafab” chip complex in Texas. It also notes Q2 2026 revenue of $7.814B and higher capex.

$SPCXMedAI 8/10

SpaceX Just Reported Earnings. Here's What History Says Happens Next.

SpaceX (SPCX) reported Q2 results as a newly public company. Total revenue rose 92% to $7.8B. Connectivity revenue increased 66% to $4.3B with operating income up 79% to $1.6B. The AI segment revenue grew 247% to $2.6B but operating losses were $1.3B. Operating losses widened to $542M. Investors will watch capex efficiency and AI revenue scaling.